Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
|Articles|April 8, 2022
WATCH: Should patients with NAION receive sleep studies?
Author(s)Andrew Lee, MD
Andrew Lee, MD, and Elizabeth Fortin, MD, briefly discuss whether all patients with NAION should receive a sleep study.
Advertisement
Andrew Lee, MD, and Elizabeth Fortin, MD, briefly discuss the pros and cons as to whether all patients with non-arteritic anterior ischemic optic neuropathy (NAION) should receive a sleep study. Looking at arguments presented by Thomas R. Hedges III, MD, and Clare Fraser, MD, Lee and Fontin reflect on the question and their own clinical practice.
Advertisement
Related to this article
Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.
Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.
Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
Alvotech files first known aflibercept 8 mg biosimilar with EMA
3
FDA approves subcutaneous Enspryng for TED
4
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
5